- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Capricor Therapeutics Inc (CAPR)
The Capricor Therapeutics share price today is 10.240, view NASDAQ CAPR stock exchange data. Track the latest Capricor Therapeutics share price with real-time updates on CAPR stock performance including market cap, day range, 52-week range and dividend yield. Access CAPR charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.868
10.950
52 wk Range
2.960
40.370
CAPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.86810.950
52 wk Range
2.96040.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CAPR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
27.250
Upside
+166.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
5 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 27.250
(+166.11% Upside)
Capricor Therapeutics Inc Earnings Call Summary for Q3/2026
- Capricor posted Q3 2026 loss of $0.73/share vs. $0.13 estimate; net loss widened to $42.7M from $24.6M year-over-year amid pre-launch spending.
- Company holds $198.5M in cash and securities, sufficient for 12+ months of operations; no ATM share sales in 2026, reducing dilution concerns.
- FDA review of lead therapy deramiocel for Duchenne muscular dystrophy ongoing, with target action date of Nov. 22, 2026; preparing independent launch.
- San Diego GMP facility operational with 250-patient annual capacity; second floor expansion expected H1 2027 to support 2,000-2,500 patients yearly.
- Workforce reduced 10% to align costs; ongoing arbitration with NS Pharma not expected to impede commercialization if approval secured.
Last Updated: 11-11-2026, 03:52 am
Read Full TranscriptEarnings
Latest Release
10-11-2026
EPS / Forecast
-0.73 / -0.13
Revenue / Forecast
-- / 41.71M
Compare CAPR to Peers and Sector
Metrics to compare | CAPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAPRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −1.6x | −0.2x | |
PEG Ratio | 0.09 | −0.04 | 0.00 | |
Price/Book | 2.8x | 2.1x | 2.6x | |
Price / LTM Sales | - | 111.4x | 2.8x | |
Upside (Analyst Target) | 166.1% | 465.5% | 63.4% | |
Fair Value Upside | Unlock | 5.3% | 9.5% | Unlock |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Capricor Therapeutics (CAPR) Share Price Today?
The Capricor Therapeutics share price today is 10.240.
What is the current Capricor Therapeutics (CAPR) share price and day range?
As of 13-11-2026, the Capricor Therapeutics share price is 10.240, with a previous close of 10.240. The share price has ranged from 9.868 to 10.950 today, while the 52-week range spans from 2.960 to 40.370.
What Is the Capricor Therapeutics Market Cap?
As of today, Capricor Therapeutics market cap is 595.380M.
What Is the Capricor Therapeutics (CAPR) Share Price Target?
The average 12-month share price target for Capricor Therapeutics is 27.250, with a high estimate of 54 and a low estimate of 10.5. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +166.11% Upside potential.
What Is Capricor Therapeutics's Earnings Per Share (TTM)?
The Capricor Therapeutics EPS (TTM) is -2.65.
When Is the Next Capricor Therapeutics Earnings Date?
Capricor Therapeutics will release its next earnings report on 11-03-2027.
From a Technical Analysis Perspective, Is CAPR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Capricor Therapeutics Trade On?
Capricor Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Capricor Therapeutics?
The stock symbol for Capricor Therapeutics is "CAPR."
How Many Times Has Capricor Therapeutics Stock Split?
Capricor Therapeutics has split 2 times.
How Many Employees Does Capricor Therapeutics Have?
Capricor Therapeutics has 231 employees.
What Is the CAPR Premarket Price?
CAPR's last pre-market stock price is 10.940. The pre-market share volume is 1,11,320.000, and the stock has changed by -0.280, or -2.500%.
What Is the CAPR After Hours Price?
CAPR's last after hours stock price is 9.900, the stock has changed by -0.340, or -3.320%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.